SLC6A3 and Parkinson disease: Eleven percent of LRRK2 non-manifesting carriers had dopamine transporter (DaT) deficits, with carriers showing higher Movement Disorders Society Unified Parkinson’s Disease Rating Scale scores and hyposmia rates than controls, suggesting LRRK2 as a predictive biomarker for PD development [58].